Genentech/Curis Hedgehog Inhibitor Gets Unclear Results In Ovarian Cancer Maintenance Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche/Genentech will "make a portfolio decision" on development of the novel Hedgehog inhibitor GDC-0449 in advanced ovarian cancer after further analyses of Phase II data, partner Curis said Aug. 9. Early analyses of top-line data "warrant additional investigation to clarify and interpret potential clinical activity," the company said
You may also be interested in...
Hedgehog stumbles in clinical trial
Curis' first-in-class Hedgehog pathway inhibitor GDC-0449 failed in a Phase II clinical trial in metastatic colorectal cancer, where it was studied in combination with partner Roche/Genentech's Avastin and FOLFOX or FOLFIRI chemotherapy, the firms announced June 16. The trial did not meet the primary endpoint of extending time from randomization to disease progression or death in patients getting the GDC-0449 combination versus the standard of care arm. Curis is confident that other trials will bear out the Hedgehog inhibitor's potential, because the pathway is thought to act by different mechanisms in other tumor types; the firm noted that proof of concept has been achieved in advanced basal cell carcinoma, which is "almost always" the result of a specific mutation in a component of the Hedgehog pathway. Roche already has a pivotal Phase II of GDC-0449 underway in advanced basal cell carcinoma and the firm has indicated it expects to initiate a Phase II in operable basal cell carcinoma during the second half of 2010. Results are also expected in the second half from a randomized Phase II in advanced ovarian cancer in a maintenance setting, "which is evaluating the ability of GDC-0449 to slow the time to recurrence in patients ... in complete remission, by impeding the residual cancer cell's ability to grow," Curis said
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product